Studies for Patients with Asthma or COPD
University of Chicago physicians are currently involved in a number of clinical studies to evaluate new medications and methods to treat diseases.
Protocol #14831A - Chest wall Oscillation for Asthma and COPD exacerbaTions II Trial
(COAT II Trial)
The University of Chicago and Dr. Jerry Krishnan, MD, PhD are conducting a pilot study of adults hospitalized for Asthma/COPD exacerbations to determine the effectiveness of high frequency chest wall oscillation (HFCWO) in the treatment of severe asthma/COPD exacerbations.
The purpose of this study is to help researchers 1) find out how patients accept or tolerate daily inpatient HFCWO during severe asthma/COPD exacerbations, and 2) collect information about the clinical effectiveness of HFCWO when added to conventional medical therapy.
For the purposes of this study, only adult patients hospitalized at the University of Chicago Medical Center for asthma or COPD exacerbations are eligible. Participants will receive either the HFCWO vest or an identically appearing sham vest. This study involves 3 daily treatments with the vest or sham (for a total of up to 7 treatments while hospialized) and will last approximately 30 days after hospital discharge. The procedures that will be done during the study include spirometry or breathing tests, health assessments, and questionnaires/surveys.
As a participant in the study, any breathing tests, etc. are done at no cost to you, and you will not have to pay for the study vest treatments. You may benefit from participation in this research study with improvement in your symptoms of asthma and COPD. However, it is possible that there may be no benefit to you. Regardless, if you decide to participate in this research study, the information obtained during this research study may be useful scientifically and may benefit future patients with asthma and COPD.
Patients will receive up to $150 for participation in this study.
Initial inclusion criteria:·
- Must be 18 years or older
- Admission to the inpatient medical floor at the University of Chicago Medical Center
- Must have a diagnosis of asthma, asthma/COPD or COPD exacerbation
- No prior use of HFCWO
Study Director: Dr.
Jerry Krishnan, MD, PhD
Department of Pulmonary and Critical Care
For more information contact the Asthma and COPD Center directly at (773) 702-0880.
A similar study is also being conducted at Mercy Hospital and Medical Center.
Protocol #15729A - Study to Assess use of Respiratory Inhalers (SARI)
Health literacy is the ability of individuals to obtain, process, and understand basic health information and services needed to make appropriate health decisions. Inadequate health literacy is a major public health concern and is associated with poor knowledge of health conditions, lower use of preventative services, higher rates of non-adherence to therapy, higher hospitalization rates, and poorer self-reported health.
Many patients with asthma and COPD use inhaled respiratory medications, often delivered via metered-dose inhalers (MDI; e.g., albuterol) and diskus devices (e.g., Advair Diskus or fluticasone/salmeterol). Unfortunately, patients often do not know how to use respiratory inhalers correctly and may therefore not benefit fully from these medications.
The purpose of the SARI study is to 1) assess the health literacy of patients hospitalized for asthma or COPD exacerbation, and 2) assess if patients hospitalized for asthma and COPD are able to use an MDI or diskus correctly.
Patients will receive $25.00 for participation in this study.
Inclusion criteria include:
- Must be 18 years or older
- Admission to the inpatient medical floor at the University of Chicago Medical Center
- Must have a diagnosis of asthma, asthma/COPD or COPD exacerbation
Study Director: Dr. Jerry Krishnan, MD, PhD
Department of Pulmonary and Critical Care
For more information contact the Asthma and COPD Center directly at (773) 702-0880.
A similar study is also being conducted at Mercy Hospital and Medical Center.
Protocol #15543B - Adult Pulmonary Clinic Registry (APCR)
The objective of this registry is to provide researchers and patients the benefits of a coordinated process by which researchers can screen and identify patients who are interested in participating in clinical research. Identification and recruitment is currently taking place in the University of Chicago Medical Center's pulmonary clinics (both general and subspecialty).
If you are interested in being listed on this registry and are currently receiving care at the University of Chicago Medical Center, please contact the Asthma and COPD Center at (773) 702-0880.
Protocol #15322B - Repeated High dose Inhaled Corticosteroids for acute asthma (ReHICS)
The purpose of this study is compare the effects of high-dose inhaled corticosteroids in addition to conventional treatment vs. conventional therapy alone in adults hospitalized for acute asthma.
Inclusion criteria:
- Must be between 18 and 50 years old
- Admission to the inpatient medical floor at the University of Chicago Medical Center
- Must have a diagnosis of asthma
Patients will receive up to $150 for participation in this study.
For more information about this study, please contact the Asthma and COPD Center directly at (773) 702-0880.
Protocol #15427A - Evaluation of Lovastatin in Severe Persistent Asthma (ELiSPA)
The purpose of this study is to evaluate the effects of lovastatin (a cholesterol lowering medication) in addition to standard care in patients with poorly controlled asthma.
Inclusion criteria:
- Age between 18 and 65 years old.
- Severe persistent asthma
- No evidence of alternate diagnosis on bronchoscopy within past 4 weeks
- Stable dose of inhaled fluticasone and inhaled salmeterol
Principal Investigators: Blanca Camoretti-Mercado, PhD; John McConville, MD
Patients will receive up to $575 for participation in this study. Recruitment has not yet started. For more information about this study, please contact the Asthma and COPD Center directly at (773) 702-0880.